have been treated with SPINRAZA*
*Based on commercial patients, early access patients, and clinical trial participants through September 2021.
‡Includes clinical trial patients.
‡Pivotal clinical studies of SPINRAZA included patients from 3 days to 16 years of age at first dose, but did not include sufficient numbers of subjects aged 65 and older to determine whether they respond differently from younger patients.
§Based on commercial patients in the US (including Puerto Rico) through December 2020.
*Based on commercial patients, early access patients, and clinical trial participants through September 2021.
†Includes clinical trial patients.
‡Pivotal clinical studies of SPINRAZA included patients from 3 days to 16 years of age at first dose, but did not include sufficient numbers of subjects aged 65 and older to determine whether they respond differently from younger patients.
§Based on commercial patients in the US (including Puerto Rico) through December 2020.